Skip to content

US · INNPF · DRUG MANUFACTURERS - SPECIALTY & GENERIC

INNOCAN PHARMA Corp (INNPF) intrinsic value and stock valuation

$1.24as of 2026-11-21 · Mkt cap 7.2M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

INNOCAN PHARMA Corp DCF and intrinsic value

InvestorsCraft values INNPF with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from INNPF’s statements →

INNOCAN PHARMA Corp Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Calgary, AB T2P 0N7 innocanpharma.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$26.6M+384.2% 5y CAGRd
20182025
Net income
-$-1.12M
20182025
Free cash flow
$480K
20182025
Total equity
$8.24M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$26.6M$29.4M$13.7M$2.56M$200K
Operating income-$-1.25M-$-1.25M$3.8M-$-6.27M-$-7.48M
Net income-$-1.12M-$-1.83M-$-4.7M-$-3.76M-$-10.05M
EPSd-$-250K-$-435.71K-$-1.22M-$-1.01M-$-2.98M
Operating cash flow$490K-$-1.58M-$-3.9M-$-6.07M-$-6.63M
Capital expenditure-$-20K-$-10K-$-50K-$-30K-$-40K
Free cash flow$480K-$-1.59M-$-3.95M-$-6.09M-$-6.67M
Total assets$10.5M$9.26M$6.94M$6.98M$12.6M
Total debt$930K$10K$30K$30K$0.00
Net debt-$-5.76M-$-5M-$-3.85M-$-4.91M-$-11.05M
Total equity$8.24M$7.02M$4.39M$6.22M$9.01M
Cash and short-term investments$6.69M$5.01M$3.88M$4.95M$11.1M
Income statement
20252024202320222021
Revenue$26.6M$29.4M$13.7M$2.56M$200K
Cost of revenue$2.68M$3.25M$1.68M$450K$70K
Gross profit$23.9M$26.2M$12M$2.11M$120K
Research and development expenses$930K$1.55M$1.8M$1.53M$1.4M
Selling, general and administrative expenses$24.3M$25.9M$14M$6.85M$6.2M
Other expenses$0.00$0.00-$-7.61M$0.00$0.00
Operating expenses$25.2M$27.4M$8.18M$8.37M$7.6M
Cost and expenses$27.9M$30.7M$9.85M$8.82M$7.68M
Interest income$0.00$0.00$20K$20K$0.00
Interest expense$0.00$10K$0.00$0.00$10K
Depreciation and amortization$40K$40K$30K$30K$40K
Ebitda$130K-$-1.21M-$-3.77M-$-3.7M-$-7.37M
Operating income-$-1.25M-$-1.25M$3.8M-$-6.27M-$-7.48M
Total other income/expenses, net$1.34M$2.17M-$-7.84M$2.38M-$-2.61M
Income before tax$90K$920K-$-4.03M-$-3.89M-$-10.09M
Income tax expense$430K$1.18M$210K$0.00$0.00
Net income-$-1.12M-$-1.83M-$-4.7M-$-3.76M-$-10.05M
Weighted average shares outstanding$4.48M$4.2M$3.86M$3.73M$3.37M
Weighted average diluted shares outstanding$4.48M$4.2M$3.86M$3.73M$3.37M
Balance sheet
20252024202320222021
Cash and short-term investments$6.69M$5.01M$3.88M$4.95M$11.1M
Net receivables$940K$690K$250K$240K$960K
Inventory$2.18M$3.32M$1.74M$1.13M$510K
Total current assets$10.4M$9.15M$6.8M$6.88M$12.5M
Property, plant and equipment, net$90K$110K$140K$100K$50K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$90K$110K$140K$100K$50K
Total assets$10.5M$9.26M$6.94M$6.98M$12.6M
Accounts payable$230K$180K$110K$100K$50K
Short-term debt$0.00$10K$20K$10K$0.00
Deferred revenue$0.00$0.00$0.00$320K$430K
Total current liabilities$1.35M$2.24M$2.54M$730K$3.56M
Long-term debt$930K$0.00$10K$20K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$930K$0.00$10K$20K$0.00
Capital lease obligations$0.00$10K$30K$30K$0.00
Total liabilities$2.29M$2.24M$2.55M$750K$3.56M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-36.03M-$-34.91M-$-33.07M-$-28.37M-$-24.61M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00-$0.00$0.00
Total equity$8.24M$7.02M$4.39M$6.22M$9.01M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$930K$10K$30K$30K$0.00
Net debt-$-5.76M-$-5M-$-3.85M-$-4.91M-$-11.05M
Cash flow statement
20252024202320222021
Net income-$-340K-$-260K-$-4.7M-$-3.89M-$-10.09M
Depreciation and amortization$40K$30K$30K$40K$40K
Stock-based compensation$1.46M$2.01M$850K$970K$2.16M
Change in working capital$1.57M-$-1.2M-$-810K-$-530K-$-970K
Accounts receivable$0.00$20K-$0.00-$-10K$0.00
Inventory$1.14M-$-1.57M-$-620K-$-620K-$-80K
Accounts payable$50K$70K$20K$40K-$-470K
Net cash provided by operating activities$490K-$-1.58M-$-3.9M-$-6.07M-$-6.63M
Investments in property, plant and equipment-$-20K-$-10K-$-50K-$-30K-$-40K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-10K$50K-$-80K-$-30K-$-50K
Common stock issued$520K$890K$2.99M$130K$3.91M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$1.15M$2.7M$2.92M$120K$15.3M
Net change in cash$1.68M$1.12M-$-1.06M-$-6.1M$8.71M
Cash at end of period$6.69M$5.01M$3.88M$4.95M$11.1M
Operating cash flow$490K-$-1.58M-$-3.9M-$-6.07M-$-6.63M
Capital expenditure-$-20K-$-10K-$-50K-$-30K-$-40K
Free cash flow$480K-$-1.59M-$-3.95M-$-6.09M-$-6.67M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About INNOCAN PHARMA Corp

        InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems by integrating cannabidiol (CBD) with diverse pharmaceutical ingredients. Its operations extend across the United States, Poland, France, and other international markets. The company actively pursues research and development into CBD-loaded exosomes for treating conditions like COVID-19, as well as advancing CBD-infused liposomes. InnoCan Pharma also commercializes a range of branded CBD-integrated pharmaceutical and topical treatment products, such as CBD eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Established in 2018, the corporation is headquartered in Calgary, Canada.

        CEO
        Iris Bincovich
        Employees
        11
        Beta
        -0.22

        Explore

        Frequently asked questions

        What is the intrinsic value of INNOCAN PHARMA Corp (INNPF)?

        InvestorsCraft does not currently publish an intrinsic value for INNPF. How the IC value is calculated.

        Is INNPF undervalued?

        InvestorsCraft does not publish an undervaluation signal for INNPF at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.